CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists and scientific and research professionals involved in basic, translational and clinical cancer research or treatment.
  
  LEARNING OBJECTIVES

  • Comprehend how DNA damage repair pathway abnormalities can be targeted via PARP inhibition to elicit benefit in cancer therapy.
  • Assess the pharmacologic, pharmacodynamic and pharmacokinetic similarities and differences among the commercially available and investigational PARP inhibitors to better understand the corresponding activity and toxicities associated with these agents.
  • Appreciate available clinical trial data with FDA-approved PARP inhibitors for patients with ovarian cancer in different disease settings, and safely integrate these agents into routine clinical care.
  • Evaluate the FDA approvals of PARP inhibitors for patients with HER2-negative metastatic breast cancer harboring a germline BRCA mutation, and discern how these agents can be appropriately and safely integrated into routine clinical practice.
  • Appraise available data evaluating olaparib as maintenance therapy for patients with pancreatic cancer with BRCA mutations whose disease has not progressed on first-line platinum-based chemotherapy, and optimally incorporate this FDA-approved treatment strategy into current management algorithms.
  • Review published clinical research findings with PARP inhibitor monotherapy for appropriately selected patients with progressive metastatic castration-resistant prostate cancer, and identify individuals for whom treatment with these agents is appropriate.
  • Understand the biologic rationale for the design of ongoing clinical trials evaluating novel therapeutic approaches with PARP inhibitors for patients with DNA damage repair deficiencies, and as applicable, enroll or refer appropriate individuals for study participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THESE CME ACTIVITIES
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Maha Hussain, MD, FACP, FASCO
  Genevieve Teuton Professor of Medicine
  Division of Hematology/Oncology
  Deputy Director
  Robert H Lurie Comprehensive Cancer Center
  Northwestern University Feinberg School of Medicine
  Chicago, Illinois
  
  Consulting Agreements: Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Pfizer Inc; CME and Educational Activity: Aptitude Health, Astellas, Sanofi Genzyme.
  
  Ursula Matulonis, MD
  Chief, Division of Gynecologic Oncology
  Brock-Wilson Family Chair
  Dana-Farber Cancer Institute
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Novartis; Consulting Agreement: Merck; Contracted Research: FUJIFILM Pharmaceuticals USA Inc, ImmunoGen Inc, Merck, Mersana Therapeutics, SQZ Biotech; Data and Safety Monitoring Board/Committee: Advaxis Inc; Travel (unpaid advisory board): AstraZeneca Pharmaceuticals LP.
  
  Philip A Philip, MD, PhD, FRCP
  Kathryn Cramer Endowed Chair in Cancer Research
  Professor of Oncology and Pharmacology
  Leader, GI and Neuroendocrine Oncology
  Karmanos Cancer Institute
  Wayne State University
  Detroit, Michigan
  
  No financial interests or affiliations to disclose.
  
  Hope S Rugo, MD
  Professor of Medicine
  Director, Breast Oncology and Clinical Trials Education
  University of California, San Francisco
  Helen Diller Family Comprehensive Cancer Center
  San Francisco, California
  
  Consulting Agreements: Puma Biotechnology Inc, Samsung Bioepis; Contracted Research: Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seattle Genetics; Paid Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, MacroGenics Inc, Merck, Mylan NV, Novartis, Pfizer Inc.
  
  

  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.

  Release date: August 2020
  Expiration date: August 2021